Hemoglobin H disease
ICD-10 D56.0 · ICD-11 3A50.02

Non-Deletional HbH Disease (--/αTα): What to Do When Regular Transfusions Fail to Maintain Target Haemoglobin

This protocol addresses patients with the non-deletional form of haemoglobin H disease who are no longer adequately managed by a regular transfusion schedule.

Clinical scenario

Haemoglobin H disease, non-deletional form — defined by the presence of a non-deletional α-globin gene mutation (--/αTα). Clinical phenotypes vary considerably among affected individuals; symptoms are generally more severe than in deletional forms of the disease.

When the previous treatment no longer suffices

The preceding line of management — regular (scheduled) blood transfusions, typically administered every 3 to 6 weeks — is considered to have failed when pre-transfusion haemoglobin can no longer be maintained at the target of 80–90 g/L, or when access to or adherence with that regimen is severely limited. This protocol describes the step taken after that point.

Next-step approach

For carefully selected patients meeting specific clinical criteria, a surgical intervention is an option. The goal is a clinically meaningful increase in haemoglobin level. The complete eligibility criteria, patient selection process, and clinical targets are set out in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

View source ↗